BRPI0806371A2 - agentes ligação de receptor nuclear - Google Patents

Info

Publication number

BRPI0806371A2

BRPI0806371A2 BRPI0806371-0A BRPI0806371A BRPI0806371A2 BR PI0806371 A2 BRPI0806371 A2 BR PI0806371A2 BR PI0806371 A BRPI0806371 A BR PI0806371A BR PI0806371 A2 BRPI0806371 A2 BR PI0806371A2

Authority

BR

Brazil

Prior art keywords

subject

nrba

binding agents

reduction

another embodiment

Prior art date

2007-01-22

Links

• Espacenet
• Global Dossier
• Discuss

• 239000011230 binding agent Substances 0.000 title claims abstract description 117
• 108020005497 Nuclear hormone receptor Proteins 0.000 title claims abstract description 69
• 108020004017 nuclear receptors Proteins 0.000 title claims abstract description 43
• 102000006255 nuclear receptors Human genes 0.000 title abstract description 4
• 238000011282 treatment Methods 0.000 claims abstract description 69
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
• 201000010099 disease Diseases 0.000 claims abstract description 24
• 210000002307 prostate Anatomy 0.000 claims abstract description 12
• 208000035475 disorder Diseases 0.000 claims abstract description 11
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 10
• 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
• 208000001132 Osteoporosis Diseases 0.000 claims abstract description 9
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
• 238000000034 method Methods 0.000 claims description 158
• 150000001875 compounds Chemical class 0.000 claims description 150
• 229910052739 hydrogen Inorganic materials 0.000 claims description 150
• 239000001257 hydrogen Substances 0.000 claims description 149
• 125000000623 heterocyclic group Chemical group 0.000 claims description 148
• 125000000217 alkyl group Chemical group 0.000 claims description 120
• -1 pharmaceutical Chemical class 0.000 claims description 117
• 239000000203 mixture Substances 0.000 claims description 114
• 125000003118 aryl group Chemical group 0.000 claims description 88
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 88
• 229910052736 halogen Inorganic materials 0.000 claims description 87
• 150000002367 halogens Chemical class 0.000 claims description 86
• 230000009467 reduction Effects 0.000 claims description 86
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 84
• 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 66
• 229910052799 carbon Inorganic materials 0.000 claims description 66
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 66
• 125000001188 haloalkyl group Chemical group 0.000 claims description 65
• 125000003342 alkenyl group Chemical group 0.000 claims description 63
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 62
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 62
• 230000002829 reductive effect Effects 0.000 claims description 62
• 229920006395 saturated elastomer Polymers 0.000 claims description 57
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 56
• 230000000694 effects Effects 0.000 claims description 55
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 54
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 54
• 150000003839 salts Chemical class 0.000 claims description 53
• 230000003111 delayed effect Effects 0.000 claims description 52
• 125000003545 alkoxy group Chemical group 0.000 claims description 42
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 41
• 125000000304 alkynyl group Chemical group 0.000 claims description 40
• 125000004122 cyclic group Chemical group 0.000 claims description 39
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 38
• 125000001072 heteroaryl group Chemical group 0.000 claims description 37
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 35
• 150000001204 N-oxides Chemical class 0.000 claims description 29
• 210000001519 tissue Anatomy 0.000 claims description 27
• 150000002148 esters Chemical group 0.000 claims description 26
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 24
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 24
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 24
• 229910052760 oxygen Inorganic materials 0.000 claims description 24
• 229940124530 sulfonamide Drugs 0.000 claims description 24
• 150000003456 sulfonamides Chemical class 0.000 claims description 24
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
• 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 22
• 125000004432 carbon atom Chemical group C* 0.000 claims description 21
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
• JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 20
• 108010081348 HRT1 protein Hairy Chemical group 0.000 claims description 20
• 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 20
• 125000004982 dihaloalkyl group Chemical group 0.000 claims description 20
• VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical group F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 20
• 125000005394 methallyl group Chemical group 0.000 claims description 20
• 150000003536 tetrazoles Chemical class 0.000 claims description 20
• 125000004385 trihaloalkyl group Chemical group 0.000 claims description 20
• 229910006074 SO2NH2 Inorganic materials 0.000 claims description 19
• 229910006069 SO3H Inorganic materials 0.000 claims description 19
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 19
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 19
• 108010038795 estrogen receptors Proteins 0.000 claims description 17
• 210000000988 bone and bone Anatomy 0.000 claims description 16
• 239000000262 estrogen Substances 0.000 claims description 16
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
• 239000003085 diluting agent Substances 0.000 claims description 14
• 229940011871 estrogen Drugs 0.000 claims description 14
• 102000005962 receptors Human genes 0.000 claims description 14
• 108020003175 receptors Proteins 0.000 claims description 14
• 208000024827 Alzheimer disease Diseases 0.000 claims description 12
• 201000001320 Atherosclerosis Diseases 0.000 claims description 12
• 108010010234 HDL Lipoproteins Proteins 0.000 claims description 12
• 102000015779 HDL Lipoproteins Human genes 0.000 claims description 12
• 108010007622 LDL Lipoproteins Proteins 0.000 claims description 12
• 102000007330 LDL Lipoproteins Human genes 0.000 claims description 12
• 239000002253 acid Substances 0.000 claims description 11
• 208000006011 Stroke Diseases 0.000 claims description 9
• 150000002632 lipids Chemical class 0.000 claims description 9
• 230000001404 mediated effect Effects 0.000 claims description 9
• 230000004792 oxidative damage Effects 0.000 claims description 9
• 208000017497 prostate disease Diseases 0.000 claims description 9
• 208000019553 vascular disease Diseases 0.000 claims description 9
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 8
• 230000027455 binding Effects 0.000 claims description 8
• 230000001965 increasing effect Effects 0.000 claims description 8
• 125000004043 oxo group Chemical group O=* 0.000 claims description 8
• 239000002243 precursor Substances 0.000 claims description 8
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 7
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 7
• 230000006378 damage Effects 0.000 claims description 7
• 230000002401 inhibitory effect Effects 0.000 claims description 7
• 229940049953 phenylacetate Drugs 0.000 claims description 7
• 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 7
• 208000010392 Bone Fractures Diseases 0.000 claims description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
• 239000000543 intermediate Substances 0.000 claims description 6
• 239000001301 oxygen Substances 0.000 claims description 6
• 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 206010061218 Inflammation Diseases 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 208000035397 Ring chromosome 7 syndrome Diseases 0.000 claims description 5
• 102000019197 Superoxide Dismutase Human genes 0.000 claims description 5
• 108010012715 Superoxide dismutase Proteins 0.000 claims description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
• 208000029742 colonic neoplasm Diseases 0.000 claims description 5
• 102000015694 estrogen receptors Human genes 0.000 claims description 5
• 230000004054 inflammatory process Effects 0.000 claims description 5
• 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
• 208000028867 ischemia Diseases 0.000 claims description 5
• 239000011707 mineral Substances 0.000 claims description 5
• 230000004770 neurodegeneration Effects 0.000 claims description 5
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
• 230000002093 peripheral effect Effects 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 201000004384 Alopecia Diseases 0.000 claims description 4
• 206010006313 Breast tenderness Diseases 0.000 claims description 4
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
• 208000006029 Cardiomegaly Diseases 0.000 claims description 4
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 4
• 206010012289 Dementia Diseases 0.000 claims description 4
• 206010019799 Hepatitis viral Diseases 0.000 claims description 4
• 208000033830 Hot Flashes Diseases 0.000 claims description 4
• 206010060800 Hot flush Diseases 0.000 claims description 4
• 208000023105 Huntington disease Diseases 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• 206010025323 Lymphomas Diseases 0.000 claims description 4
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
• 206010063493 Premature ageing Diseases 0.000 claims description 4
• 208000032038 Premature aging Diseases 0.000 claims description 4
• 206010071019 Prostatic dysplasia Diseases 0.000 claims description 4
• 206010054880 Vascular insufficiency Diseases 0.000 claims description 4
• 206010003246 arthritis Diseases 0.000 claims description 4
• 230000004087 circulation Effects 0.000 claims description 4
• 108020004067 estrogen-related receptors Proteins 0.000 claims description 4
• 208000024963 hair loss Diseases 0.000 claims description 4
• 230000003676 hair loss Effects 0.000 claims description 4
• 201000001421 hyperglycemia Diseases 0.000 claims description 4
• 208000017169 kidney disease Diseases 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 230000009245 menopause Effects 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 208000024891 symptom Diseases 0.000 claims description 4
• 208000023577 vascular insufficiency disease Diseases 0.000 claims description 4
• 201000001862 viral hepatitis Diseases 0.000 claims description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
• WZKNWOSGBYOMOR-UHFFFAOYSA-N 4-bromo-2-(4-fluorophenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(F)C=C1 WZKNWOSGBYOMOR-UHFFFAOYSA-N 0.000 claims description 2
• XRAULIOBQVWAHA-UHFFFAOYSA-N 5-bromo-8-hydroxy-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound BrC=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 XRAULIOBQVWAHA-UHFFFAOYSA-N 0.000 claims description 2
• GCJZYOIXXVVQKC-UHFFFAOYSA-N 6-hydroxy-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C=2C1=CC(O)=CC=2 GCJZYOIXXVVQKC-UHFFFAOYSA-N 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 4
• 206010002383 Angina Pectoris Diseases 0.000 claims 3
• 206010014733 Endometrial cancer Diseases 0.000 claims 3
• 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
• 208000010412 Glaucoma Diseases 0.000 claims 3
• 208000010496 Heart Arrest Diseases 0.000 claims 3
• 206010029096 Neoplasm prostate Diseases 0.000 claims 3
• 208000031481 Pathologic Constriction Diseases 0.000 claims 3
• 208000017442 Retinal disease Diseases 0.000 claims 3
• 206010038923 Retinopathy Diseases 0.000 claims 3
• 206010064930 age-related macular degeneration Diseases 0.000 claims 3
• 230000001413 cellular effect Effects 0.000 claims 3
• 235000012000 cholesterol Nutrition 0.000 claims 3
• 208000029078 coronary artery disease Diseases 0.000 claims 3
• 230000000968 intestinal effect Effects 0.000 claims 3
• 201000010901 lateral sclerosis Diseases 0.000 claims 3
• 230000003902 lesion Effects 0.000 claims 3
• 208000002780 macular degeneration Diseases 0.000 claims 3
• 208000005264 motor neuron disease Diseases 0.000 claims 3
• 208000010125 myocardial infarction Diseases 0.000 claims 3
• 230000008506 pathogenesis Effects 0.000 claims 3
• 201000007094 prostatitis Diseases 0.000 claims 3
• 208000037803 restenosis Diseases 0.000 claims 3
• 208000017520 skin disease Diseases 0.000 claims 3
• 208000037804 stenosis Diseases 0.000 claims 3
• 230000036262 stenosis Effects 0.000 claims 3
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
• TVOCNPSVVIIQRF-LZCJLJQNSA-N (e)-3-[6,8-dihydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinolin-4-yl]prop-2-enoic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(/C=C/C(=O)O)=CN1C1=CC=C(O)C=C1 TVOCNPSVVIIQRF-LZCJLJQNSA-N 0.000 claims 1
• RQUQUZXEFIIGJT-UNXLUWIOSA-N (e)-3-[6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinolin-4-yl]prop-2-enoic acid Chemical compound O=C1C2=CC=C(O)C=C2C(/C=C/C(=O)O)=CN1C1=CC=C(O)C=C1 RQUQUZXEFIIGJT-UNXLUWIOSA-N 0.000 claims 1
• KJAKOSACJWWFAE-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxy-1-oxoisoquinoline-4-carbonitrile Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1C(C#N)=CN2C1=CC=C(O)C(F)=C1 KJAKOSACJWWFAE-UHFFFAOYSA-N 0.000 claims 1
• MEDJRANHIIJXIE-UHFFFAOYSA-N 4,5-dibromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C(Br)=C2C(Br)=C1 MEDJRANHIIJXIE-UHFFFAOYSA-N 0.000 claims 1
• IWXWZDBKLIOSJS-UHFFFAOYSA-N 5-bromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C(Br)=C2C=C1 IWXWZDBKLIOSJS-UHFFFAOYSA-N 0.000 claims 1
• QAGWYKCFYYZWRQ-NSCUHMNNSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-4-[(e)-prop-1-enyl]isoquinolin-1-one Chemical compound O=C1C2=C(O)C=C(O)C=C2C(/C=C/C)=CN1C1=CC=C(O)C=C1 QAGWYKCFYYZWRQ-NSCUHMNNSA-N 0.000 claims 1
• UKTXTSFJQVTSDF-UHFFFAOYSA-N 8-hydroxy-2-(4-hydroxyphenyl)-6-methoxy-1-oxoisoquinoline-5-carbonitrile Chemical compound N#CC=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 UKTXTSFJQVTSDF-UHFFFAOYSA-N 0.000 claims 1
• NRIXVJQZYRQYPG-UHFFFAOYSA-N [4-chloro-6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinolin-8-yl] trifluoromethanesulfonate Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(OS(=O)(=O)C(F)(F)F)C=C(OC)C=C2C(Cl)=C1 NRIXVJQZYRQYPG-UHFFFAOYSA-N 0.000 claims 1
• 125000002015 acyclic group Chemical group 0.000 claims 1
• 230000002490 cerebral effect Effects 0.000 claims 1
• 230000002265 prevention Effects 0.000 abstract description 9
• 229940088597 hormone Drugs 0.000 abstract description 6
• 239000005556 hormone Substances 0.000 abstract description 6
• 208000012902 Nervous system disease Diseases 0.000 abstract description 3
• 208000025966 Neurological disease Diseases 0.000 abstract description 3
• 230000036542 oxidative stress Effects 0.000 abstract description 3
• 208000008589 Obesity Diseases 0.000 abstract description 2
• 235000020824 obesity Nutrition 0.000 abstract description 2
• 208000037765 diseases and disorders Diseases 0.000 abstract 1
• 208000027866 inflammatory disease Diseases 0.000 abstract 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 120
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 86
• 150000002431 hydrogen Chemical class 0.000 description 86
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 85
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
• 239000000243 solution Substances 0.000 description 46
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 45
• 238000003756 stirring Methods 0.000 description 43
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
• 150000003053 piperidines Chemical class 0.000 description 40
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
• 235000019439 ethyl acetate Nutrition 0.000 description 37
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
• 239000003795 chemical substances by application Substances 0.000 description 35
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 35
• 125000000753 cycloalkyl group Chemical group 0.000 description 34
• 102100029951 Estrogen receptor beta Human genes 0.000 description 33
• 108010041356 Estrogen Receptor beta Proteins 0.000 description 31
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 31
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 30
• 238000006243 chemical reaction Methods 0.000 description 28
• 102100038595 Estrogen receptor Human genes 0.000 description 27
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 26
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
• 238000010992 reflux Methods 0.000 description 26
• 230000015572 biosynthetic process Effects 0.000 description 25
• 238000003786 synthesis reaction Methods 0.000 description 25
• 150000001412 amines Chemical class 0.000 description 24
• 238000003818 flash chromatography Methods 0.000 description 24
• 239000002207 metabolite Substances 0.000 description 23
• 239000008194 pharmaceutical composition Substances 0.000 description 23
• 229960001866 silicon dioxide Drugs 0.000 description 23
• 239000007787 solid Substances 0.000 description 23
• 239000000741 silica gel Substances 0.000 description 22
• 229910002027 silica gel Inorganic materials 0.000 description 22
• 125000001424 substituent group Chemical group 0.000 description 22
• 210000003739 neck Anatomy 0.000 description 21
• 238000005160 1H NMR spectroscopy Methods 0.000 description 20
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
• 150000001299 aldehydes Chemical class 0.000 description 20
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 20
• 239000012265 solid product Substances 0.000 description 20
• 201000011510 cancer Diseases 0.000 description 19
• 239000012300 argon atmosphere Substances 0.000 description 18
• 210000004027 cell Anatomy 0.000 description 18
• 239000002904 solvent Substances 0.000 description 18
• 125000002252 acyl group Chemical group 0.000 description 17
• 150000003973 alkyl amines Chemical class 0.000 description 17
• 239000005557 antagonist Substances 0.000 description 17
• 239000003446 ligand Substances 0.000 description 17
• 125000004103 aminoalkyl group Chemical group 0.000 description 16
• 239000000460 chlorine Substances 0.000 description 16
• 101710196141 Estrogen receptor Proteins 0.000 description 15
• 239000000556 agonist Substances 0.000 description 15
• 239000013078 crystal Substances 0.000 description 15
• 239000012535 impurity Substances 0.000 description 15
• 229940002612 prodrug Drugs 0.000 description 15
• 239000000651 prodrug Substances 0.000 description 15
• 239000012044 organic layer Substances 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 150000001649 bromium compounds Chemical group 0.000 description 13
• 150000001805 chlorine compounds Chemical group 0.000 description 13
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 13
• 150000002222 fluorine compounds Chemical group 0.000 description 13
• 125000004438 haloalkoxy group Chemical group 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
• 125000005265 dialkylamine group Chemical group 0.000 description 12
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 12
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 12
• 239000000725 suspension Substances 0.000 description 12
• 239000002246 antineoplastic agent Substances 0.000 description 11
• 150000004694 iodide salts Chemical group 0.000 description 11
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
• 235000019341 magnesium sulphate Nutrition 0.000 description 11
• 239000003921 oil Substances 0.000 description 11
• 235000019198 oils Nutrition 0.000 description 11
• 229910052786 argon Inorganic materials 0.000 description 10
• 238000001816 cooling Methods 0.000 description 10
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
• 239000000284 extract Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 239000002671 adjuvant Substances 0.000 description 9
• 125000002837 carbocyclic group Chemical group 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• 230000003637 steroidlike Effects 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 9
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 9
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
• 239000003098 androgen Substances 0.000 description 8
• 239000012267 brine Substances 0.000 description 8
• 229940022399 cancer vaccine Drugs 0.000 description 8
• 238000009566 cancer vaccine Methods 0.000 description 8
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
• 239000000839 emulsion Substances 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 230000003078 antioxidant effect Effects 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 238000013270 controlled release Methods 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 229910052740 iodine Inorganic materials 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 239000003642 reactive oxygen metabolite Substances 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000001914 filtration Methods 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 150000003431 steroids Chemical class 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 6
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
• 229910015845 BBr3 Inorganic materials 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 229940125388 beta agonist Drugs 0.000 description 5
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
• 239000008121 dextrose Substances 0.000 description 5
• 125000000262 haloalkenyl group Chemical group 0.000 description 5
• 150000003840 hydrochlorides Chemical class 0.000 description 5
• 230000003308 immunostimulating effect Effects 0.000 description 5
• 239000011630 iodine Substances 0.000 description 5
• VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 229940044601 receptor agonist Drugs 0.000 description 5
• 239000000018 receptor agonist Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 229960005486 vaccine Drugs 0.000 description 5
• PTHRFKANAKCVAH-UHFFFAOYSA-N 1-(2-piperidin-1-ylethoxy)isoquinolin-6-ol Chemical compound N=1C=CC2=CC(O)=CC=C2C=1OCCN1CCCCC1 PTHRFKANAKCVAH-UHFFFAOYSA-N 0.000 description 4
• BIUDJVBDYHJCCR-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(Br)=C1 BIUDJVBDYHJCCR-UHFFFAOYSA-N 0.000 description 4
• YECTYKMUECXIIC-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C=2C=CC=CC=2)=C1 YECTYKMUECXIIC-UHFFFAOYSA-N 0.000 description 4
• DDLJWWYULDUBGA-UHFFFAOYSA-N 6-methoxy-2h-isoquinolin-1-one Chemical compound OC1=NC=CC2=CC(OC)=CC=C21 DDLJWWYULDUBGA-UHFFFAOYSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
• 102100032187 Androgen receptor Human genes 0.000 description 4
• 206010065687 Bone loss Diseases 0.000 description 4
• 229920000858 Cyclodextrin Polymers 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• 208000002193 Pain Diseases 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 229930003316 Vitamin D Natural products 0.000 description 4
• 238000009167 androgen deprivation therapy Methods 0.000 description 4
• 108010080146 androgen receptors Proteins 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 229910052791 calcium Inorganic materials 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 4
• ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 4
• 229940097362 cyclodextrins Drugs 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000002480 mineral oil Substances 0.000 description 4
• 235000010446 mineral oil Nutrition 0.000 description 4
• 230000036407 pain Effects 0.000 description 4
• 239000004031 partial agonist Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 150000002989 phenols Chemical class 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
• 102000003998 progesterone receptors Human genes 0.000 description 4
• 108090000468 progesterone receptors Proteins 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 125000004001 thioalkyl group Chemical group 0.000 description 4
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 150000003710 vitamin D derivatives Chemical class 0.000 description 4
• 229940046008 vitamin d Drugs 0.000 description 4
• SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 3
• JHMDJCQHWGALEV-UHFFFAOYSA-N 4-bromo-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C=C1 JHMDJCQHWGALEV-UHFFFAOYSA-N 0.000 description 3
• VACHIUUKYZPGPP-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(Br)=C1 VACHIUUKYZPGPP-UHFFFAOYSA-N 0.000 description 3
• OOOIOILEQULOBV-UHFFFAOYSA-N 4-bromo-6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C(Br)=C1 OOOIOILEQULOBV-UHFFFAOYSA-N 0.000 description 3
• DEDJPVYPSZIEAL-UHFFFAOYSA-N 4-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C=C)=C1 DEDJPVYPSZIEAL-UHFFFAOYSA-N 0.000 description 3
• HKNUGPCAHQCTKA-UHFFFAOYSA-N 8-hydroxy-6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(O)C=C(OC)C=C2C=C1 HKNUGPCAHQCTKA-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Natural products C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
• 239000001856 Ethyl cellulose Substances 0.000 description 3
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
• 235000010469 Glycine max Nutrition 0.000 description 3
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
• 229920002907 Guar gum Polymers 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 3
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
• 206010020880 Hypertrophy Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• 229930182821 L-proline Natural products 0.000 description 3
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 3
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 3
• 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 229920002125 Sokalan® Polymers 0.000 description 3
• 206010041549 Spinal cord compression Diseases 0.000 description 3
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 108010085012 Steroid Receptors Proteins 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 3
• 125000004414 alkyl thio group Chemical group 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 229960002932 anastrozole Drugs 0.000 description 3
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 239000003886 aromatase inhibitor Substances 0.000 description 3
• 235000010323 ascorbic acid Nutrition 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 229960001631 carbomer Drugs 0.000 description 3
• 150000001735 carboxylic acids Chemical class 0.000 description 3
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 229940099112 cornstarch Drugs 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 239000002178 crystalline material Substances 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 239000002254 cytotoxic agent Substances 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 235000019325 ethyl cellulose Nutrition 0.000 description 3
• 229920001249 ethyl cellulose Polymers 0.000 description 3
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
• 229940093471 ethyl oleate Drugs 0.000 description 3
• 229960000255 exemestane Drugs 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 229940014259 gelatin Drugs 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 229940045109 genistein Drugs 0.000 description 3
• 235000006539 genistein Nutrition 0.000 description 3
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 3
• 229960002154 guar gum Drugs 0.000 description 3
• 239000000665 guar gum Substances 0.000 description 3
• 235000010417 guar gum Nutrition 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000001361 intraarterial administration Methods 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 229960003881 letrozole Drugs 0.000 description 3
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 230000009826 neoplastic cell growth Effects 0.000 description 3
• SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 3
• 239000012457 nonaqueous media Substances 0.000 description 3
• 150000002895 organic esters Chemical class 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 150000004707 phenolate Chemical class 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 235000013824 polyphenols Nutrition 0.000 description 3
• 229960002429 proline Drugs 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 238000010791 quenching Methods 0.000 description 3
• 230000000580 secretagogue effect Effects 0.000 description 3
• 239000000849 selective androgen receptor modulator Substances 0.000 description 3
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 229940083542 sodium Drugs 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 239000011973 solid acid Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 102000005969 steroid hormone receptors Human genes 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 229940021747 therapeutic vaccine Drugs 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• 235000019166 vitamin D Nutrition 0.000 description 3
• 239000011710 vitamin D Substances 0.000 description 3
• CNOAOQSZNOTZLQ-OIBXWCBGSA-N (2r,4as,10ar)-4a-benzyl-2-(2-chloroethynyl)-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol Chemical compound C([C@]12CC[C@@](O)(C[C@H]2CCC=2C1=CC=C(C=2)O)C#CCl)C1=CC=CC=C1 CNOAOQSZNOTZLQ-OIBXWCBGSA-N 0.000 description 2
• WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 2
• HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 2
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 2
• UJVDJAPJQWZRFR-DHIUTWEWSA-N 2-amino-n-[(2r)-1-[[(1r)-1-formamido-2-(1h-indol-3-yl)ethyl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound C1=CC=C2C(C[C@@H](NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3)NC(=O)C(C)(N)C)NC=O)=CNC2=C1 UJVDJAPJQWZRFR-DHIUTWEWSA-N 0.000 description 2
• LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 102000008873 Angiotensin II receptor Human genes 0.000 description 2
• 108050000824 Angiotensin II receptor Proteins 0.000 description 2
• 229940122815 Aromatase inhibitor Drugs 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 102100035882 Catalase Human genes 0.000 description 2
• 108010053835 Catalase Proteins 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 229940102550 Estrogen receptor antagonist Drugs 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010017076 Fracture Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 108010016122 Ghrelin Receptors Proteins 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
• JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000029725 Metabolic bone disease Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 229920000881 Modified starch Polymers 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 102000004067 Osteocalcin Human genes 0.000 description 2
• 108090000573 Osteocalcin Proteins 0.000 description 2
• 206010049088 Osteopenia Diseases 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108700005075 Regulator Genes Proteins 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• 240000006661 Serenoa repens Species 0.000 description 2
• 235000005318 Serenoa repens Nutrition 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 208000005250 Spontaneous Fractures Diseases 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 235000019486 Sunflower oil Nutrition 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 244000269722 Thea sinensis Species 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 229940062527 alendronate Drugs 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Chemical class 0.000 description 2
• 229930188824 alisol Natural products 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 150000008052 alkyl sulfonates Chemical class 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 230000001548 androgenic effect Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000000118 anti-neoplastic effect Effects 0.000 description 2
• 235000009697 arginine Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 2
• 229960000817 bazedoxifene Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• 230000010072 bone remodeling Effects 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
• 235000010418 carrageenan Nutrition 0.000 description 2
• 239000000679 carrageenan Substances 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 229940113118 carrageenan Drugs 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 125000006165 cyclic alkyl group Chemical group 0.000 description 2
• 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 2
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 229940048820 edetates Drugs 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 230000001076 estrogenic effect Effects 0.000 description 2
• 235000019441 ethanol Nutrition 0.000 description 2
• 229960004667 ethyl cellulose Drugs 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 235000019688 fish Nutrition 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 2
• 235000009569 green tea Nutrition 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 239000003111 growth hormone derivative Substances 0.000 description 2
• 239000003324 growth hormone secretagogue Substances 0.000 description 2
• UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 2
• 239000003906 humectant Substances 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 229960001438 immunostimulant agent Drugs 0.000 description 2
• 239000003022 immunostimulating agent Substances 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 239000004026 insulin derivative Substances 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 150000002496 iodine Chemical class 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
• CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
• 235000008696 isoflavones Nutrition 0.000 description 2
• 239000003394 isomerase inhibitor Substances 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229940039781 leptin Drugs 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 229960004999 lycopene Drugs 0.000 description 2
• 235000012661 lycopene Nutrition 0.000 description 2
• OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
• 239000001751 lycopene Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
• CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
• IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
• 239000002661 non steroidal estrogen Substances 0.000 description 2
• 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 125000005474 octanoate group Chemical class 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 2
• 229960003969 ospemifene Drugs 0.000 description 2
• 150000003891 oxalate salts Chemical class 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 229960001802 phenylephrine Drugs 0.000 description 2
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229920001987 poloxamine Polymers 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 229940021993 prophylactic vaccine Drugs 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• 239000003087 receptor blocking agent Substances 0.000 description 2
• 239000010018 saw palmetto extract Substances 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008174 sterile solution Substances 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000003460 sulfonic acids Chemical class 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 239000002600 sunflower oil Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 229960001967 tacrolimus Drugs 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
• KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
• 229960005026 toremifene Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
• 230000035903 transrepression Effects 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 230000006442 vascular tone Effects 0.000 description 2
• 235000013311 vegetables Nutrition 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
• GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• DFELGYQKEOCHOA-RBXNTRDFSA-N (11r,13s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CCC3C3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-RBXNTRDFSA-N 0.000 description 1
• FVGXANXBVWECQE-BYWGDBCOSA-N (2e,4e)-5-(7-methoxy-3,3-dimethyl-2h-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid Chemical compound O1CC(C)(C)C=C(\C=C\C(\C)=C\C(O)=O)C2=CC(OC)=CC=C21 FVGXANXBVWECQE-BYWGDBCOSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• WDSPVCXWXOIFRA-HUVFLSCGSA-N (2r,4as,10ar)-4a-benzyl-2-prop-1-ynyl-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol Chemical compound C([C@]12CC[C@](C[C@H]2CCC=2C1=CC=C(O)C=2)(O)C#CC)C1=CC=CC=C1 WDSPVCXWXOIFRA-HUVFLSCGSA-N 0.000 description 1
• JKMJQRRLCJXPOK-QWHCGFSZSA-N (2r,5s)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-n-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide Chemical compound C([C@H](C)N(C[C@H]1C)C=2C=C(C(C#N)=CC=2)C(F)(F)F)N1C(=O)NC1=CC=C(C(F)(F)F)N=C1 JKMJQRRLCJXPOK-QWHCGFSZSA-N 0.000 description 1
• NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
• KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 description 1
• WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 description 1
• WMUIIGVAWPWQAW-DEOSSOPVSA-N (2s)-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-DEOSSOPVSA-N 0.000 description 1
• NEHWBYHLYZGBNO-BVEPWEIPSA-N (2s)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)C(C)(N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 NEHWBYHLYZGBNO-BVEPWEIPSA-N 0.000 description 1
• RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
• HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
• INTCGJHAECYOBW-APWZRJJASA-N (2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-ol Chemical compound C([C@](O)([C@@H](CN(C)C)C)C=1C=CC=CC=1)C1=CC=CC=C1 INTCGJHAECYOBW-APWZRJJASA-N 0.000 description 1
• AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
• WQBIOEFDDDEARX-CHWSQXEVSA-N (4ar,10br)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one Chemical compound C1CC2=CC(Cl)=CC=C2[C@@H]2[C@@H]1N(C)C(=O)CC2 WQBIOEFDDDEARX-CHWSQXEVSA-N 0.000 description 1
• SEOPOTXFVGEDGX-UPHHSBJESA-N (4bs,7r,8ar)-4b-benzyl-7-hydroxy-7-prop-1-ynyl-n-(pyridin-3-ylmethyl)-5,6,8,8a,9,10-hexahydrophenanthrene-2-carboxamide Chemical compound C([C@]12CC[C@](C[C@H]2CCC=2C1=CC=C(C=2)C(=O)NCC=1C=NC=CC=1)(O)C#CC)C1=CC=CC=C1 SEOPOTXFVGEDGX-UPHHSBJESA-N 0.000 description 1
• ACYYHAZVNHMRMQ-XKZIYDEJSA-N (5z)-5-[(2-fluoro-3-methylphenyl)methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical compound C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C1=CC=CC(C)=C1F ACYYHAZVNHMRMQ-XKZIYDEJSA-N 0.000 description 1
• UKVVNEHFNYKGMX-KIVPVIKRSA-N (8r,9s,10r,13s,14r)-14-hydroxy-10,13-dimethyl-2,7,8,9,11,12,15,16-octahydro-1h-cyclopenta[a]phenanthrene-3,6,17-trione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@]4(O)[C@@H]3CC(=O)C2=C1 UKVVNEHFNYKGMX-KIVPVIKRSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 description 1
• GNGSOPFGGKKDQP-UHFFFAOYSA-N (phosphonoamino)phosphonic acid Chemical compound OP(O)(=O)NP(O)(O)=O GNGSOPFGGKKDQP-UHFFFAOYSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• CDUKGEKMAXMMBR-UHFFFAOYSA-N 1,2-dichloro-4-[(3,4-dichlorophenyl)methoxymethyl]benzene Chemical compound C1=C(Cl)C(Cl)=CC=C1COCC1=CC=C(Cl)C(Cl)=C1 CDUKGEKMAXMMBR-UHFFFAOYSA-N 0.000 description 1
• SAHNWXKZHPLKQM-UHFFFAOYSA-N 1-adamantyl hydrogen carbonate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)O)C3 SAHNWXKZHPLKQM-UHFFFAOYSA-N 0.000 description 1
• FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
• LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
• PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
• WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical class CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
• SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
• HRNNEXGXEPNTMP-UHFFFAOYSA-N 1-methylsulfinyl-4-[(4-methylsulfinylphenyl)methoxymethyl]benzene Chemical compound C1=CC(S(=O)C)=CC=C1COCC1=CC=C(S(C)=O)C=C1 HRNNEXGXEPNTMP-UHFFFAOYSA-N 0.000 description 1
• ARARQWKFKMWCDL-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1COCC1=CC=CC=C1[N+]([O-])=O ARARQWKFKMWCDL-UHFFFAOYSA-N 0.000 description 1
• CZSDJYXNNJQXBB-UHFFFAOYSA-N 10-methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline Chemical compound N1C(C)(C)C=C(C)C2=C1C=CC1=C2C(CC=C)OC2=C1C(OC)=CC=C2 CZSDJYXNNJQXBB-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• FXXJKNJNKAXPLH-UHFFFAOYSA-N 2,3,5,6-tetrafluoro-4-(2,3,5,6-tetrafluoropyridin-4-yl)oxypyridine Chemical compound FC1=NC(F)=C(F)C(OC=2C(=C(F)N=C(F)C=2F)F)=C1F FXXJKNJNKAXPLH-UHFFFAOYSA-N 0.000 description 1
• CYOPMEZSMPDHMG-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-6-hydroxy-4-iodoisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(I)=CN2C1=CC=C(O)C(F)=C1 CYOPMEZSMPDHMG-UHFFFAOYSA-N 0.000 description 1
• YZBDHJCQDCMPRH-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-8-hydroxy-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C(F)=C1 YZBDHJCQDCMPRH-UHFFFAOYSA-N 0.000 description 1
• TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• SCWPNMHQRGNQHH-AATRIKPKSA-N 2-[(e)-2-carboxyethenyl]benzoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1C(O)=O SCWPNMHQRGNQHH-AATRIKPKSA-N 0.000 description 1
• MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• OUEODVPKPRQETQ-OCZCAGDBSA-N 2-chloro-4-[(1R,5S)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl]-3-methylbenzonitrile Chemical compound CC1=C(Cl)C(C#N)=CC=C1N1[C@@H]2CC[C@H]1CC(C)(O)C2 OUEODVPKPRQETQ-OCZCAGDBSA-N 0.000 description 1
• KEJORAMIZFOODM-PWSUYJOCSA-N 2-chloro-4-[(7r,7as)-7-hydroxy-1,3-dioxotetrahydro-1h-pyrrolo[1,2-c]imidazol-2(3h)-yl]-3-methylbenzonitrile Chemical compound CC1=C(Cl)C(C#N)=CC=C1N1C(=O)N2CC[C@@H](O)[C@H]2C1=O KEJORAMIZFOODM-PWSUYJOCSA-N 0.000 description 1
• CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
• NSSOSHDCWCMNDM-UHFFFAOYSA-N 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile Chemical compound C1=C(C#N)C2=CC(O)=CC=C2C=C1C1=CC=C(O)C(F)=C1 NSSOSHDCWCMNDM-UHFFFAOYSA-N 0.000 description 1
• 108090000117 3-alpha-(17-beta)-hydroxysteroid dehydrogenase (NAD(+)) Proteins 0.000 description 1
• ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
• HRDCVMSNCBAMAM-UHFFFAOYSA-N 3-prop-2-ynoxyprop-1-yne Chemical compound C#CCOCC#C HRDCVMSNCBAMAM-UHFFFAOYSA-N 0.000 description 1
• DZOKENUNRMDZCS-UHFFFAOYSA-N 3h-isoquinolin-4-one Chemical class C1=CC=C2C(=O)CN=CC2=C1 DZOKENUNRMDZCS-UHFFFAOYSA-N 0.000 description 1
• VRZVKIJRJRBQJT-UHFFFAOYSA-N 4-(2,3-dihydro-1-benzofuran-7-yl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC2=C1OCC2 VRZVKIJRJRBQJT-UHFFFAOYSA-N 0.000 description 1
• OKVFFYVPQHKSRD-UHFFFAOYSA-N 4-(4-propylpyrazol-1-yl)phenol Chemical compound OC1=CC=C(C=C1)N1N=CC(=C1)CCC OKVFFYVPQHKSRD-UHFFFAOYSA-N 0.000 description 1
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
• JTSSUEWTRDWHGY-UHFFFAOYSA-N 4-(pyridin-4-ylmethoxymethyl)pyridine Chemical compound C=1C=NC=CC=1COCC1=CC=NC=C1 JTSSUEWTRDWHGY-UHFFFAOYSA-N 0.000 description 1
• SWKPKONEIZGROQ-UHFFFAOYSA-M 4-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-M 0.000 description 1
• OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
• GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 description 1
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
• FVVPWVFWOOMXEZ-ZIADKAODSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 FVVPWVFWOOMXEZ-ZIADKAODSA-N 0.000 description 1
• NVASIMIVHIFTEL-UHFFFAOYSA-N 4-[3-(4-hydroxyphenyl)-2-bicyclo[2.2.2]oct-2-enyl]phenol Chemical compound C1=CC(O)=CC=C1C1=C(C=2C=CC(O)=CC=2)C2CCC1CC2 NVASIMIVHIFTEL-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
• IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• CJNRHMOCAFYPNU-UHFFFAOYSA-N 4-bromo-2-(3-fluoro-4-hydroxyphenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C(F)=C1 CJNRHMOCAFYPNU-UHFFFAOYSA-N 0.000 description 1
• ZKBLJFLHWBORNQ-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(3-hydroxyphenyl)isoquinolin-1-one Chemical compound OC1=CC=CC(N2C(C3=CC=C(O)C=C3C(Br)=C2)=O)=C1 ZKBLJFLHWBORNQ-UHFFFAOYSA-N 0.000 description 1
• XLWHIKVCZRUROX-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)isoquinoline-1-thione Chemical compound C1=CC(O)=CC=C1N1C(=S)C2=CC=C(O)C=C2C(Br)=C1 XLWHIKVCZRUROX-UHFFFAOYSA-N 0.000 description 1
• NJMAAQGAVWIPET-UHFFFAOYSA-N 4-bromo-6-methoxy-2-(4-methoxyphenyl)-1h-isoquinoline Chemical compound C1=CC(OC)=CC=C1N1C=C(Br)C2=CC(OC)=CC=C2C1 NJMAAQGAVWIPET-UHFFFAOYSA-N 0.000 description 1
• KDIJFTYBJBYCJT-UHFFFAOYSA-N 4-bromo-8-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C=C)C=C(O)C=C2C(Br)=C1 KDIJFTYBJBYCJT-UHFFFAOYSA-N 0.000 description 1
• AZVDUDPENBFRBD-UHFFFAOYSA-N 4-chloro-2-(3-fluoro-4-hydroxyphenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Cl)=CN2C1=CC=C(O)C(F)=C1 AZVDUDPENBFRBD-UHFFFAOYSA-N 0.000 description 1
• KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
• INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 description 1
• HWLLYFXDDGGHOE-BCSUUIJWSA-N 6-[(2r,5r)-2-methyl-5-[(1r)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-4-(trifluoromethyl)-1h-quinolin-2-one Chemical compound C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1C1=CC=C(NC(=O)C=C2C(F)(F)F)C2=C1 HWLLYFXDDGGHOE-BCSUUIJWSA-N 0.000 description 1
• ULBPQWIGZUGPHU-UHFFFAOYSA-N 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)quinolin-2(1h)-one Chemical compound N1C(=O)C=C(C(F)(F)F)C2=CC(N(CC(F)(F)F)CC(F)(F)F)=CC=C21 ULBPQWIGZUGPHU-UHFFFAOYSA-N 0.000 description 1
• SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
• BVCSBABZBDLYNM-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC(O)=CC=C1C1=O)=CN1C1=CC=C(O)C=C1 BVCSBABZBDLYNM-UHFFFAOYSA-N 0.000 description 1
• DWJWQCHKPAXAQA-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-iodoisoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(I)=C1 DWJWQCHKPAXAQA-UHFFFAOYSA-N 0.000 description 1
• NLICMTXFTAFGFM-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C=C1 NLICMTXFTAFGFM-UHFFFAOYSA-N 0.000 description 1
• LCHGFAHHVISDQP-UHFFFAOYSA-N 6-hydroxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(O)C=C2C=C1 LCHGFAHHVISDQP-UHFFFAOYSA-N 0.000 description 1
• LRIYURUHCZKVOW-UHFFFAOYSA-N 6-methoxy-1-(2-piperidin-1-ylethoxy)isoquinoline Chemical compound N=1C=CC2=CC(OC)=CC=C2C=1OCCN1CCCCC1 LRIYURUHCZKVOW-UHFFFAOYSA-N 0.000 description 1
• FATGBXBWZTXROD-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-1h-isoquinoline-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C=C(C#N)C2=CC(OC)=CC=C2C1 FATGBXBWZTXROD-UHFFFAOYSA-N 0.000 description 1
• QDBXREDOQFLXOU-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-4-phenylisoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C(C=2C=CC=CC=2)=C1 QDBXREDOQFLXOU-UHFFFAOYSA-N 0.000 description 1
• XWGJIIQTSLZFQU-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C=C1 XWGJIIQTSLZFQU-UHFFFAOYSA-N 0.000 description 1
• LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
• 229960005508 8-azaguanine Drugs 0.000 description 1
• UCDBLYHPJMMFMY-UHFFFAOYSA-N 8-bromoquinoline-4-carbonitrile Chemical class C1=CN=C2C(Br)=CC=CC2=C1C#N UCDBLYHPJMMFMY-UHFFFAOYSA-N 0.000 description 1
• XMQDHAVDMCJSCU-UHFFFAOYSA-N 8-hydroxy-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 XMQDHAVDMCJSCU-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 102100027211 Albumin Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 101800002638 Alpha-amanitin Proteins 0.000 description 1
• 231100000729 Amatoxin Toxicity 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 241000219193 Brassicaceae Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
• QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
• XUYAUTVZRNBJAT-UHFFFAOYSA-N CS(=O)C1=CC=C(COC(O)=O)C=C1 Chemical compound CS(=O)C1=CC=C(COC(O)=O)C=C1 XUYAUTVZRNBJAT-UHFFFAOYSA-N 0.000 description 1
• 101100007418 Caenorhabditis elegans cox-5A gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 108010073254 Colicins Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• 108010041986 DNA Vaccines Proteins 0.000 description 1
• 229940021995 DNA vaccine Drugs 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 229940127406 Estrogen Receptor Agonists Drugs 0.000 description 1
• 229940122880 Estrogen receptor agonist Drugs 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
• DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 101800001586 Ghrelin Proteins 0.000 description 1
• 102400000442 Ghrelin-28 Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 description 1
• 101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
• 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010058359 Hypogonadism Diseases 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• VMGWGDPZHXPFTC-HYBUGGRVSA-N Izonsteride Chemical compound CN([C@@H]1CCC2=C3)C(=O)CC[C@]1(C)C2=CC=C3SC(S1)=NC2=C1C=CC=C2CC VMGWGDPZHXPFTC-HYBUGGRVSA-N 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• 150000000994 L-ascorbates Chemical class 0.000 description 1
• GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• 108090000856 Lyases Proteins 0.000 description 1
• 102000004317 Lyases Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
• 206010027452 Metastases to bone Diseases 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 108010056852 Myostatin Proteins 0.000 description 1
• NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
• LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 108010042309 Netropsin Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
• QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
• 108010015181 PPAR delta Proteins 0.000 description 1
• 101150014691 PPARA gene Proteins 0.000 description 1
• WVIUOSJLUCTGFK-UHFFFAOYSA-N Pactamycin Natural products CC=1C=CC=C(O)C=1C(=O)OCC1(O)C(O)(C)C(C(O)C)(NC(=O)N(C)C)C(N)C1NC1=CC=CC(C(C)=O)=C1 WVIUOSJLUCTGFK-UHFFFAOYSA-N 0.000 description 1
• UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
• 206010034156 Pathological fracture Diseases 0.000 description 1
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 229940079156 Proteasome inhibitor Drugs 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 229940123934 Reductase inhibitor Drugs 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
• RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• XYRWDMXUDDAXMF-UHFFFAOYSA-N Sesquicillin Natural products C=C1CCC2C(CCC=C(C)C)(C)C(OC(C)=O)CCC2(C)C1CC1=C(O)C(C)=C(C)OC1=O XYRWDMXUDDAXMF-UHFFFAOYSA-N 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
• 240000006394 Sorghum bicolor Species 0.000 description 1
• 229930184317 Streptovaricin Natural products 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
• 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
• NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
• FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
• 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
• WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 description 1
• SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
• GBBBPWVJGMFZGX-UHFFFAOYSA-N [(cyclohexylamino)-phosphonomethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCC1 GBBBPWVJGMFZGX-UHFFFAOYSA-N 0.000 description 1
• OEKMGABCSLYWOP-DHUJRADRSA-N [4-[(2s)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(OC(=O)C(C)(C)C)C=C3O2)C)C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=CC=C1OCCN1CCCCC1 OEKMGABCSLYWOP-DHUJRADRSA-N 0.000 description 1
• ZKJVCUXZMYKTLT-UHFFFAOYSA-N [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile Chemical compound C1=CC(O)=CC=C1C1=CC2=CC(O)=CC(CC#N)=C2O1 ZKJVCUXZMYKTLT-UHFFFAOYSA-N 0.000 description 1
• USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
• 108010023617 abarelix Proteins 0.000 description 1
• 229960002184 abarelix Drugs 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
• 239000000999 acridine dye Substances 0.000 description 1
• 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000007172 age related pathology Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229950004900 alfaprostol Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 239000004007 alpha amanitin Substances 0.000 description 1
• CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
• CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• ZOZLFBZFMZKVFW-UHFFFAOYSA-N aluminum;zinc Chemical compound [Al+3].[Zn+2] ZOZLFBZFMZKVFW-UHFFFAOYSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical compound NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 239000003263 anabolic agent Substances 0.000 description 1
• 230000001195 anabolic effect Effects 0.000 description 1
• 238000009165 androgen replacement therapy Methods 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 108010070670 antarelix Proteins 0.000 description 1
• 150000001454 anthracenes Chemical class 0.000 description 1
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003712 anti-aging effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 description 1
• 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000001484 arginines Chemical class 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 238000005899 aromatization reaction Methods 0.000 description 1
• 125000005002 aryl methyl group Chemical group 0.000 description 1
• 125000005228 aryl sulfonate group Chemical group 0.000 description 1
• MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
• 229950005529 arzoxifene Drugs 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 229950004810 atamestane Drugs 0.000 description 1
• PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• PYLVMUGLVSEAHK-UHFFFAOYSA-N benzoyloxymethoxymethyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCOCOC(C1=CC=CC=C1)=O PYLVMUGLVSEAHK-UHFFFAOYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229950008527 bexlosteride Drugs 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• FFHBJDQSGDNCIV-MFVUMRCOSA-N bremelanotide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(O)=O)C1=CC=CC=C1 FFHBJDQSGDNCIV-MFVUMRCOSA-N 0.000 description 1
• 108010072543 bremelanotide Proteins 0.000 description 1
• 229950000740 bremelanotide Drugs 0.000 description 1
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical class BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 238000007816 calorimetric assay Methods 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229950004826 capromorelin Drugs 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960002115 carboquone Drugs 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000005961 cardioprotection Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
• 108700008462 cetrorelix Proteins 0.000 description 1
• 229960003230 cetrorelix Drugs 0.000 description 1
• JDECNKBYILMOLE-CJQFIEQYSA-N chembl1255887 Chemical compound O1COC(=C(C)C2=O)C3=C1\C(C)=C\[C@@](C)(O)[C@H](O)[C@@H](C)[C@@H](O)[C@H](C(=O)OC)[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C/C=C(C)/C(=O)NC1=C(C)C(OC(C)=O)=C3C2=C1O JDECNKBYILMOLE-CJQFIEQYSA-N 0.000 description 1
• JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
• DPAMLAKLEWYMGF-UHFFFAOYSA-N chembl187392 Chemical compound C1=CC(O)=CC=C1C1=NC2=CC(O)=CC=C2O1 DPAMLAKLEWYMGF-UHFFFAOYSA-N 0.000 description 1
• DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229940124443 chemopreventive agent Drugs 0.000 description 1
• 239000012627 chemopreventive agent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
• 229960003608 clomifene Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125876 compound 15a Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
• OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
• OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• OCDXZFSOHJRGIL-UHFFFAOYSA-N cyclohexyloxycyclohexane Chemical compound C1CCCCC1OC1CCCCC1 OCDXZFSOHJRGIL-UHFFFAOYSA-N 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 108091007930 cytoplasmic receptors Proteins 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
• 229950006689 darglitazone Drugs 0.000 description 1
• 125000005534 decanoate group Chemical class 0.000 description 1
• 229950006309 delmadinone Drugs 0.000 description 1
• CGBCCZZJVKUAMX-DFXBJWIESA-N delmadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 CGBCCZZJVKUAMX-DFXBJWIESA-N 0.000 description 1
• 229940029030 dendritic cell vaccine Drugs 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• OFQNFLLLCMQNEP-MIPXGPCFSA-N deterelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OFQNFLLLCMQNEP-MIPXGPCFSA-N 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 108700027435 detirelix Proteins 0.000 description 1
• 229950003747 detirelix Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
• 150000004656 dimethylamines Chemical class 0.000 description 1
• XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
• 229960004199 dutasteride Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002828 effect on organs or tissue Effects 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 108700032313 elcatonin Proteins 0.000 description 1
• 229960000756 elcatonin Drugs 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000003617 erythrocyte membrane Anatomy 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• AWYNYGDVTNSMIS-UHFFFAOYSA-N ethanamine;ethanol Chemical compound CCN.CCO AWYNYGDVTNSMIS-UHFFFAOYSA-N 0.000 description 1
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 150000002169 ethanolamines Chemical class 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 150000002171 ethylene diamines Chemical class 0.000 description 1
• 229940009626 etidronate Drugs 0.000 description 1
• 229950001583 examorelin Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 229950011548 fadrozole Drugs 0.000 description 1
• ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
• 229950003707 farglitazar Drugs 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 description 1
• 229950001083 finrozole Drugs 0.000 description 1
• 229950004684 fispemifene Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001506 fluorescence spectroscopy Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 229940028334 follicle stimulating hormone Drugs 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229960004675 fusidic acid Drugs 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
• 229960003794 ganirelix Drugs 0.000 description 1
• 108700032141 ganirelix Proteins 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
• 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
• 108700020746 histrelin Proteins 0.000 description 1
• 229960002193 histrelin Drugs 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• YPQLFJODEKMJEF-UHFFFAOYSA-N hydroxyflutamide Chemical compound CC(C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YPQLFJODEKMJEF-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 229950006971 incadronic acid Drugs 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 230000019948 ion homeostasis Effects 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 108010027047 ipamorelin Proteins 0.000 description 1
• 229950002987 ipamorelin Drugs 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• GPVPDRHTRGTSIH-UHFFFAOYSA-N isoquinolin-6-ol Chemical compound C1=NC=CC2=CC(O)=CC=C21 GPVPDRHTRGTSIH-UHFFFAOYSA-N 0.000 description 1
• 150000002537 isoquinolines Chemical class 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 108010083551 iturelix Proteins 0.000 description 1
• QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
• 229950004528 iturelix Drugs 0.000 description 1
• 229950004319 izonsteride Drugs 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
• 229960002367 lasofoxifene Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 108010018656 leptin (116-130) Proteins 0.000 description 1
• 102000005861 leptin receptors Human genes 0.000 description 1
• 108010019813 leptin receptors Proteins 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229940058352 levulinate Drugs 0.000 description 1
• OMXGOGXEWUCLFI-UHFFFAOYSA-N lgd-3303 Chemical compound N1C(=O)C=C(Cl)C2=C1C=CC1=C2C(C)=C(CC)N1CC(F)(F)F OMXGOGXEWUCLFI-UHFFFAOYSA-N 0.000 description 1
• 229950007056 liarozole Drugs 0.000 description 1
• UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002634 lipophilic molecules Chemical class 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 239000002697 lyase inhibitor Substances 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 150000002669 lysines Chemical class 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 238000006140 methanolysis reaction Methods 0.000 description 1
• ZUVAACFIEPYYOP-UHFFFAOYSA-N methoxycyclopropane Chemical compound COC1CC1 ZUVAACFIEPYYOP-UHFFFAOYSA-N 0.000 description 1
• OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 description 1
• JYQQWQJCEUMXQZ-UHFFFAOYSA-N methyl cyanate Chemical compound COC#N JYQQWQJCEUMXQZ-UHFFFAOYSA-N 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical class CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• 150000003956 methylamines Chemical class 0.000 description 1
• 108700008455 metreleptin Proteins 0.000 description 1
• 229960000668 metreleptin Drugs 0.000 description 1
• QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
• 229950009847 meturedepa Drugs 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 229950011570 minamestane Drugs 0.000 description 1
• DAKHYLIFCYPHQW-KZQROQTASA-N minamestane Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1N DAKHYLIFCYPHQW-KZQROQTASA-N 0.000 description 1
• VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
• 229950011129 minodronic acid Drugs 0.000 description 1
• 229950008642 miproxifene Drugs 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 230000001114 myogenic effect Effects 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
• FQJIZXBCOKNLMR-FTAPQOLWSA-N n-butyl-11-[(7r,8r,9s,13s,14s,16r,17r)-16-chloro-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-n-methylundecanamide Chemical compound C1C[C@]2(C)[C@@H](O)[C@H](Cl)C[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 FQJIZXBCOKNLMR-FTAPQOLWSA-N 0.000 description 1
• MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
• 229960000210 nalidixic acid Drugs 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000037125 natural defense Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
• 229950010733 neridronic acid Drugs 0.000 description 1
• 229950001628 netoglitazone Drugs 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 150000002814 niacins Chemical class 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 150000005480 nicotinamides Chemical class 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 229960002950 novobiocin Drugs 0.000 description 1
• YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
• 102000027419 nuclear receptor subfamilies Human genes 0.000 description 1
• 108091008607 nuclear receptor subfamilies Proteins 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical class N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229960000464 oxandrolone Drugs 0.000 description 1
• 229950008266 oxeglitazar Drugs 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000010627 oxidative phosphorylation Effects 0.000 description 1
• 229960000321 oxolinic acid Drugs 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 108010011957 ozarelix Proteins 0.000 description 1
• 229950008505 ozarelix Drugs 0.000 description 1
• WVIUOSJLUCTGFK-JUJPXXQGSA-N pactamycin Chemical compound N([C@H]1[C@H](N)[C@@]([C@@]([C@]1(COC(=O)C=1C(=CC=CC=1C)O)O)(C)O)(NC(=O)N(C)C)[C@@H](O)C)C1=CC=CC(C(C)=O)=C1 WVIUOSJLUCTGFK-JUJPXXQGSA-N 0.000 description 1
• 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
• 229940046231 pamidronate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 229960001914 paromomycin Drugs 0.000 description 1
• UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 108700027320 pegylated leptin Proteins 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000036581 peripheral resistance Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• 239000003075 phytoestrogen Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
• 229950001100 piposulfan Drugs 0.000 description 1
• 125000005547 pivalate group Chemical group 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 150000003058 platinum compounds Chemical class 0.000 description 1
• 229950004541 plomestane Drugs 0.000 description 1
• JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 150000008442 polyphenolic compounds Chemical class 0.000 description 1
• 108010026466 polyproline Proteins 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• QPMDWIOUHQWKHV-ODZAUARKSA-M potassium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical class [K+].OC(=O)\C=C/C([O-])=O QPMDWIOUHQWKHV-ODZAUARKSA-M 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960000208 pralmorelin Drugs 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• FCXYSEXZEGPLGG-DHDCSXOGSA-N prinaberel Chemical compound O1C=2C(C=C)=CC(O)=CC=2N\C1=C1/C=CC(=O)C(F)=C1 FCXYSEXZEGPLGG-DHDCSXOGSA-N 0.000 description 1
• 229950001082 prinaberel Drugs 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 229940030749 prostate cancer vaccine Drugs 0.000 description 1
• 239000003207 proteasome inhibitor Substances 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 239000000007 protein synthesis inhibitor Substances 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• YLHJACXHRQQNQR-UHFFFAOYSA-N pyridine;2,4,6-tris(ethenyl)-1,3,5,2,4,6-trioxatriborinane Chemical compound C1=CC=NC=C1.C=CB1OB(C=C)OB(C=C)O1 YLHJACXHRQQNQR-UHFFFAOYSA-N 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical compound N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229950008257 ragaglitazar Drugs 0.000 description 1
• 108010092834 ramorelix Proteins 0.000 description 1
• 229950000277 ramorelix Drugs 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229940089617 risedronate Drugs 0.000 description 1
• XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
• 229950010764 rivoglitazone Drugs 0.000 description 1
• QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
• 229950005230 rogletimide Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 229960000268 spectinomycin Drugs 0.000 description 1
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
• 206010041569 spinal fracture Diseases 0.000 description 1
• 108010042747 stallimycin Proteins 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 125000003107 substituted aryl group Chemical class 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 108010064878 tabimorelin Proteins 0.000 description 1
• 229950008131 tabimorelin Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
• YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
• CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
• 229950004704 tesaglitazar Drugs 0.000 description 1
• 229950007967 tesmilifene Drugs 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229950011372 teverelix Drugs 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003567 thiocyanates Chemical class 0.000 description 1
• NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
• 229940063214 thiostrepton Drugs 0.000 description 1
• 229930188070 thiostrepton Natural products 0.000 description 1
• NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
• 229960004824 triptorelin Drugs 0.000 description 1
• 229960000875 trofosfamide Drugs 0.000 description 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
• 229950006929 uredepa Drugs 0.000 description 1
• 229940096973 urethral suppository Drugs 0.000 description 1
• 239000006217 urethral suppository Substances 0.000 description 1
• 208000037964 urogenital cancer Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 230000000304 vasodilatating effect Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 229960001771 vorozole Drugs 0.000 description 1
• XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 229960005502 α-amanitin Drugs 0.000 description 1